Sellas Life Sciences Group Inc (SLS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Sellas Life Sciences Group Inc stock (SLS) is currently trading at $5.30. Sellas Life Sciences Group Inc PS ratio (Price-to-Sales) is 26.90. Analyst consensus price target for SLS is $8.67. WallStSmart rates SLS as Sell.
- SLS PE ratio analysis and historical PE chart
- SLS PS ratio (Price-to-Sales) history and trend
- SLS intrinsic value — DCF, Graham Number, EPV models
- SLS stock price prediction 2025 2026 2027 2028 2029 2030
- SLS fair value vs current price
- SLS insider transactions and insider buying
- Is SLS undervalued or overvalued?
- Sellas Life Sciences Group Inc financial analysis — revenue, earnings, cash flow
- SLS Piotroski F-Score and Altman Z-Score
- SLS analyst price target and Smart Rating
Sellas Life Sciences Group Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Sellas Life Sciences Group Inc (SLS) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around return on equity and price/sales. Significant fundamental concerns warrant caution or avoidance.
Sellas Life Sciences Group Inc (SLS) Key Strengths (0)
Supporting Valuation Data
Sellas Life Sciences Group Inc (SLS) Areas to Watch (6)
Company is destroying shareholder value
Revenue declining -82.50%, a shrinking business
Very expensive at 26.9x annual revenue
Very expensive at 13.9x book value
Low institutional interest, mostly retail-driven
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Sellas Life Sciences Group Inc (SLS) Detailed Analysis Report
Overall Assessment
This company scores 12/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 0 register as strengths (avg 0/10) while 6 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, Price/Sales. Some valuation metrics including Price/Sales (26.90), Price/Book (13.89) suggest expensive pricing. Growth concerns include Revenue Growth at -82.50%, which may limit upside. Profitability pressure is visible in Return on Equity at -66.90%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -66.90% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -82.50% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
SLS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
SLS's Price-to-Sales ratio of 26.90x sits near its historical average of 26.9x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 0% below its historical high of 26.9x set in Mar 2026, and 0% above its historical low of 26.9x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Sellas Life Sciences Group Inc (SLS) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Sellas Life Sciences Group Inc operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Revenue contracted 83% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -5M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 2.21, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Sellas Life Sciences Group Inc.
Bottom Line
Sellas Life Sciences Group Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Sellas Life Sciences Group Inc(SLS)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
SELLAS Life Sciences Group, Inc., an advanced-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for various indications of cancer in the United States. The company is headquartered in New York, New York.